In vivo immunomodulatory effects of adipose-derived mesenchymal stem cells conditioned medium in experimental autoimmune encephalomyelitis

Immunology Letters

Volumn 172, Issue , 2016, Pages 94-105

  Yousefi, Forouzan ^a   Ebtekar, Massoumeh ^a   Soudi, Sara ^a   Soleimani, Masoud ^a   Hashemi, Seyed Mahmoud ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adipose tissue mesenchymal stem cells; Conditioned medium; Experimental autoimmune encephalomyelitis; Immunomudulatory; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3; CYTOKINE;

ADIPOSE DERIVED STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CELL; CD4+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; ADIPOSE TISSUE; ANIMAL; BRAIN; C57BL MOUSE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CONDITIONED MEDIUM; CYTOLOGY; DISEASE MODEL; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; METABOLISM; MULTIPLE SCLEROSIS;

ADIPOSE TISSUE; ANIMALS; BRAIN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84960449721     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2016.02.016     Document Type: Article

References (67)

1. Hawkes C.H. Multiple sclerosis genetics is dead. Multiple Scler. Relat. Disord. 2013, 2:156-161.
2. Ojeda E., Díaz-Cortes D., Rosales D., Duarte-Rey C., Anaya J.-M., Rojas-Villarraga A. Prevalence and clinical features of multiple sclerosis in Latin America. Clin. Neurol. Neurosurg. 2013, 115:381-387.
3. Murray T.J. The history of multiple sclerosis: the changing frame of the disease over the centuries. J. Neurol. Sci. 2009, 277(Suppl. 1):S3-8.
4. Ransohoff R.M. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 2012, 15:1074-1077.
5. Gelfand A.A., Gelfand J.M., Goadsby P.J. Migraine and multiple sclerosis: epidemiology and approach to treatment. Multiple Scler. Relat. Disord. 2013, 2:73-79.
6. Mulakayala N., Rao P., Iqbal J., Bandichhor R., Oruganti S. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview. Eur. J. Med. Chem. 2013, 60:170-186.
7. Teixeira M.Z. Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude. Homeopathy 2013, 102:215-224.
8. Zafranskaya M.M., Nizheharodova D.B., Yurkevich M.Y., Lamouskaya N.V., Motuzova Y.M., Bagatka S.S., et al. In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients. Immunol. Lett. 2013, 149:9-18.
9. Dazzi F., Krampera M. Mesenchymal stem cells and autoimmune diseases. Best Pract. Res. Clin. Haematol. 2011, 24:49-57.
10. Constantin G., Marconi S., Rossi B., Angiari S., Calderan L., Anghileri E., et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells (Dayton, Ohio) 2009, 27:2624-2635.
11. Figueroa F.E., Carrion F., Villanueva S., Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol. Res. 2012, 45:269-277.
12. Kassis I., Petrou P., Halimi M., Karussis D. Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors. Immunol. Lett. 2013, 154:70-76.
13. Rafei M., Birman E., Forner K., Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol. Ther. 2009, 17:1799-1803.
14. Kassis I., Petrou P., Halimi M., Karussis D. Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors. Immunol. Lett. 2013, 154:70-76.
15. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
16. Chamberlain G., Fox J., Ashton B., Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells (Dayton, Ohio) 2007, 25:2739-2749.
17. Wang S., Qu X., Zhao R. Clinical applications of mesenchymal stem cells. J. Hematol. Oncol. 2012, 5:19.
18. Otto W., Wright N. Mesenchymal stem cells: from experiment to clinic. Fibrogenes. Tissue Repair 2011, 4:20.
19. Lin F. Adipose tissue-derived mesenchymal stem cells: a fat chance of curing kidney disease[quest]. Kidney Int. 2012, 82:731-733.
20. Park D., Yang G., Bae D.K., Lee S.H., Yang Y.-H., Kyung J., et al. Human adipose tissue-derived mesenchymal stem cells improve cognitive function and physical activity in ageing mice. J. Neurosci. Res. 2013, 91:660-670.
21. report c. Stem cell research:charting new directions for california. 2005. 98.
22. Ostenfeld T., Caldwell M.A., Prowse K.R., Linskens M.H., Jauniaux E., Svendsen C.N. Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. Exp. Neurol. 2000, 164:215-226.
23. Juengst E., Fossel M. THe ethics of embryonic stem cells-now and forever, cells without end. JAMA 2000, 284:3180-3184.
24. Newall D.R., Beedles K.E. The stem-cell test-a novel in vitro assay for teratogenic potential. Toxicol. In Vitro 1994, 8:697-701.
25. Mizuno H. Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. J. Nippon Med. School = Nippon Ika Daigaku zasshi 2009, 76:56-66.
26. Cho Y.J., Song H.S., Bhang S., Lee S., Kang B.G., Lee J.C., et al. Therapeutic effects of human adipose stem cell-conditioned medium on stroke. J. Neurosci. Res. 2012, 90:1794-1802.
27. TodorovaI E.I., Bochev I., Dimitrov R., Belemezova K., Mourdjeva M., Kyurkchiev S., et al. Conditioned medium from adipose tissue-derived mesenchymal stem cells induces CD4 + FOXP3 + cells and increases IL-10 secretion. J. Biomed. Biotechnol. 2012, 2012:295167.
28. Hashemi S.M., Hassan Z.M., Pourfathollah A.A., Soudi S., Shafiee A., Soleimani M., et al. Comparative immunomodulatory properties of adipose-derived mesenchymal stem cells conditioned media from BALB/c, C57BL/6 and DBA mouse strains. J. Cell. Biochem. 2013, 114:955-965.
29. Dameshghi S., Zavaran-Hosseini A., Soudi S., Shirazi F.J., Nojehdehi S., Hashemi S.M. Mesenchymal stem cells alter macrophage immune responses to Leishmania major infection in both susceptible and resistance mice. Immunol. Lett. 2015, 170:15-26.
30. Petersdorf E.W. HLA matching in allogeneic stem cell transplantation. Curr. Opin. Hematol. 2004, 11:386-391.
31. Embryo Ethics The moral logic of stem-cell research. N. Engl. J. Med. 2004, 351:207-209.
32. Ben-David U., Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 2011, 11:268-277.
33. Kooreman N.G., Wu J.C. Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J. R. Soc. Interface 2010, 7:S753-S763.
34. Blum B., Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv. Cancer Res. 2008, 100:133-158.
35. Ho A.D., Wagner W., Mahlknecht U. Stem cells and ageing. EMBO Rep. 2005, 6:S35-S38.
36. Barbash I.M., Chouraqui P., Baron J., Feinberg M.S., Etzion S., Tessone A., et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003, 108:863-886. (868).
37. Xagorari A., Siotou E., Yiangou M., Tsolaki E., Bougiouklis D., Sakkas L., et al. Protective effect of mesenchymal stem cell-conditioned medium on hepatic cell apoptosis after acute liver injury. Int. J. Clin. Exp. Pathol. 2013, 6:831-840.
38. Sun J., Zhou H., Deng Y., Zhang Y., Gu P., Ge S., et al. Conditioned medium from bone marrow mesenchymal stem cells transiently retards osteoblast differentiation by downregulating runx2. Cells Tissues Organs 2012, 196:510-522.
39. Ionescu L., Byrne R.N., van Haaften T., Vadivel A., Alphonse R.S., Rey-Parra G.J., et al. Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 303:L967-L977.
40. Timmers L., Lim S.K., Hoefer I.E., Arslan F., Lai R.C., van Oorschot A.A., et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res. 2011, 6:206-214.
41. Zheng F., Li X., Zhang L., Kong X., Guo L.Y., Yang J.Y., et al. Effect of conditioned medium of mesenchymal stem cells on proliferation, migration and adhesion of human umbilical vein endothelial cells. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui = J. Exp. Hematol. Chin. Assoc. Pathophysiol. 2012, 20:154-158.
42. Du Z., Wei C., Cheng K., Han B., Yan J., Zhang M., et al. Mesenchymal stem cell-conditioned medium reduces liver injury and enhances regeneration in reduced-size rat liver transplantation. J. Surg. Res. 2013, 183:907-915.
43. Yousefi F., Ebtekar M., Soleimani M., Soudi S., Hashemi S.M. Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). Int. Immunopharmacol. 2013, 17:608-616.
44. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
45. Gerdoni E., Gallo B., Casazza S., Musio S., Bonanni I., Pedemonte E., et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann. Neurol. 2007, 61:219-227.
46. Leblanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 2003, 57:11-20.
47. Lee J.W., Fang X., Krasnodembskaya A., Howard J.P., Matthay M.A. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells (Dayton, Ohio) 2011, 29:913-919.
48. Kang J.W., Kang K.S., Koo H.C., Park J.R., Choi E.W., Park Y.H. Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells. Stem Cells Dev. 2008, 17:681-693.
49. Bassi E.J., de Almeida D.C., Moraes-Vieira P.M., Camara N.O. Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells. Stem Cell Rev. 2012, 8:329-342.
50. Bai L., Lennon D.P., Caplan A.I., DeChant A., Hecker J., Kranso J., et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 2012, 15:862-870.
51. Bai L., Lennon D.P., Caplan A.I., DeChant A., Hecker J., Kranso J., et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 2012, 15:862-870.
52. Harris V.K., Yan Q.J., Vyshkina T., Sahabi S., Liu X., Sadiq S.A. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J. Neurol. Sci. 2012, 313:167-177.
53. Luz-Crawford P., Kurte M., Bravo-Alegria J., Contreras R., Nova-Lamperti E., Tejedor G., et al. Mesenchymal stem cells generate a CD4 + CD25 + Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res. Ther. 2013, 4:65.
54. Maccario R., Podesta M., Moretta A., Cometa A., Comoli P., Montagna D., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90:516-525.
55. Engela A.U., Baan C.C., Dor F.J., Weimar W., Hoogduijn M.J. On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front. Immunol. 2012, 3:126.
56. Ghannam S., Pene J., Moquet-Torcy G., Jorgensen C., Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 2010, 185:302-312.
57. Fletcher J.M., Lalor S.J., Sweeney C.M., Tubridy N., Mills K.H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 2010, 162:1-11.
58. O'Brien K., Gran B., Rostami A. T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunotherapy 2009, 2:99-115.
59. Rafei M., Campeau P.M., Aguilar-Mahecha A., Buchanan M., Williams P., Birman E., et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 2009, 182:5994-6002.
60. Lee M.J., Kim J., Kim M.Y., Bae Y.S., Ryu S.H., Lee T.G., et al. Proteomic analysis of tumor necrosis factor-alpha-induced secretome of human adipose tissue-derived mesenchymal stem cells. J. Proteome Res. 2010, 9:1754-1762.
61. Kupcova Skalnikova H. Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie 2013, 95:2196-2211.
62. Drago D., Cossetti C., Iraci N., Gaude E., Musco G., Bachi A., et al. The stem cell secretome and its role in brain repair. Biochimie 2013, 95:2271-2285.
63. Kapur S.K., Katz A.J. Review of the adipose derived stem cell secretome. Biochimie 2013, 95:2222-2228.
64. Ribeiro C.A., Fraga J.S., Graos M., Neves N.M., Reis R.L., Gimble J.M., et al. The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations. Stem Cell Res. Ther. 2012, 3:18.
65. Chiellini C., Cochet O., Negroni L., Samson M., Poggi M., Ailhaud G., et al. Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol. Biol. 2008, 9:26.
66. Lopez-Verrilli M.A., Caviedes A., Cabrera A., Sandoval S., Wyneken U., Khoury M. Mesenchymal stem cell-derived exosomes from different sources selectively promote neuritic outgrowth. Neuroscience 2016.
67. Bonafede R., Scambi I., Peroni D., Potrich V., Boschi F., Benati D., et al. Exosome derived from murine adipose-derived stromal cells: neuroprotective effect on in vitro model of amyotrophic lateral sclerosis. Exp. Cell Res. 2016, 340:150-158.